RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31

RIGEL PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$46.72+0.75 (+1.63%)

Close on Oct 19, 2026

Community

Notes and questions about Rigel Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Rigel Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 27, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RIGL.

Revenue growth3.3% · median 181.6%

Gross margin91.4% · median 83.4%

Operating margin31.5% · median -81.0%

Net margin116.3% · median -88.2%

Advertisement
300 × 250